



EY Entrepreneur of the year-2013



FROST & SULLIVAN  
Best Practices-2013



Business today/YES bank  
Excellence Awards-2013



**Date: June 26, 2020**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e. JUNE 26, 2020**

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. June 26, 2020 duly approved and took on record the Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2020.

We hereby declare that M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors of the Company has issued its Audit Report with unmodified opinion on the standalone and the consolidated Financial Results of the Company for the year ended 31<sup>st</sup> March, 2020.

Please find enclosed herewith the duly signed Audited Standalone Financial Results and the Audited Consolidated Financial Results for the quarter and year ended March 31, 2020 alongwith the Auditor's Report.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 4:40 P.M.

This is for your information and record.

**For Eris Lifesciences Limited**

**Milind Talegaonkar**  
**Company Secretary and Compliance Officer**

**Encl.:a/a**

**Registered & Corporate Office:**

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
ERIS LIFESCIENCES LIMITED**

**Opinion and Conclusion**

We have (a) audited the Standalone Financial Results for the year ended March 31, 2020 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2020 of **ERIS LIFESCIENCES LIMITED** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2020:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

**(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2020**

With respect to the Standalone Financial Results for the quarter ended March 31, 2020, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2020**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Statement**

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2020 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the net profit and other comprehensive loss and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.



## **Auditor's Responsibilities**

### **(a) Audit of the Standalone Financial Results for the year ended March 31, 2020**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2020 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.



Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Standalone Financial Results for the quarter ended March 31, 2020**

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Other Matters**

- As stated in Note 9 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year then ended and the published year to date figures up to the third quarter of the previous financial year ended March 31, 2019. We have not issued a separate limited review report on the results and figures for the quarter ended March 31, 2019.

Our report on the Statement is not modified in respect of this matter.



**Deloitte  
Haskins & Sells LLP**

- The Statement includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama  
(Partner)  
(Membership No. 107723)  
(UDIN: 20107723AAAAGX9942)

Mumbai, June 26, 2020



EY Entrepreneur  
of the year-2013



FROST & SULLIVAN  
Best Practices-2013



Business today/YES bank  
Excellence Awards-2013

**Eris**  
Eris Lifesciences Limited

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

Particulars	[₹ in Million except per share data]				
	For Quarter Ended			For Year Ended	
	March 31, 2020 (refer note 9)	December 31, 2019 (Unaudited)	March 31, 2019 (refer note 9)	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>Revenue from Operations</b>					
Sale of products	2,260.83	2,494.79	1,946.12	10,037.60	8,811.28
Other operating income	46.54	47.90	38.18	164.71	154.11
<b>Total Revenue from Operations</b>	<b>2,307.37</b>	<b>2,542.69</b>	<b>1,984.30</b>	<b>10,202.31</b>	<b>8,965.39</b>
Other Income	(7.97)	79.06	116.00	147.28	324.99
<b>Total Income</b>	<b>2,299.40</b>	<b>2,621.75</b>	<b>2,100.30</b>	<b>10,349.59</b>	<b>9,290.38</b>
<b>Expenses</b>					
Cost of materials consumed	240.18	191.27	115.44	768.81	581.88
Purchase of stock-in-trade	106.72	148.83	294.78	700.02	875.61
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(17.88)	70.30	(106.75)	174.72	(133.99)
Employee benefits expense	510.06	491.96	410.38	1,917.32	1,667.66
Finance Costs	2.62	3.41	43.83	18.54	227.93
Depreciation and amortisation expense	129.67	113.47	100.35	448.82	315.89
Other expenses	735.88	892.45	651.25	3,085.44	2,637.64
	<b>1,707.25</b>	<b>1,911.69</b>	<b>1,509.28</b>	<b>7,113.67</b>	<b>6,172.62</b>
<b>Profit before Tax</b>	<b>592.15</b>	<b>710.06</b>	<b>591.02</b>	<b>3,235.92</b>	<b>3,117.76</b>
<b>Tax Expense</b>					
Current Tax	104.85	127.03	132.17	574.92	688.67
Deferred Tax	(63.77)	(43.73)	(65.31)	(251.74)	(424.72)
<b>Total Tax Expense</b>	<b>41.08</b>	<b>83.30</b>	<b>66.86</b>	<b>323.18</b>	<b>263.95</b>
<b>Net Profit for the period / year</b>	<b>551.07</b>	<b>626.76</b>	<b>524.16</b>	<b>2,912.74</b>	<b>2,853.81</b>
<b>Other Comprehensive Income</b>	<b>(6.66)</b>	<b>(0.65)</b>	<b>(1.98)</b>	<b>(11.71)</b>	<b>(0.99)</b>
Items that will not be reclassified to profit or loss	(10.23)	(1.00)	(3.05)	(18.00)	(1.52)
Income tax relating to items that will not be reclassified to profit or loss	3.57	0.35	1.07	6.29	0.53
<b>Total Comprehensive Income</b>	<b>544.41</b>	<b>626.11</b>	<b>522.18</b>	<b>2,901.03</b>	<b>2,852.82</b>
Paid Up Equity Share Capital (Face Value of ₹ 1 each)				135.78	137.52
Other Equity				12,861.23	11,422.55
Earnings Per Share (of ₹ 1 each) (not annualised) :					
Basic	4.05	4.55	3.81	21.23	20.75
Diluted	4.04	4.55	3.81	21.21	20.74

See accompanying notes to the standalone financial results

*Signature*  
ERIS LIFESCIENCES LTD.

Registered & Corporate Office:

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

Notes to the financial results

1. Statement of Standalone Assets and Liabilities

(₹ in Million)

Particulars	As at	As at
	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>I. ASSETS :</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment	789.01	538.33
(b) Right-of-use asset	51.24	-
(c) Capital work-in-progress	-	7.48
(d) Goodwill	166.60	166.60
(e) Other Intangible assets	4,999.55	4,133.54
(f) Intangible assets under development	43.73	19.82
(g) Financial assets		
Investments	2,460.28	2,743.63
Other financial assets	82.37	76.18
(h) Income tax assets (net)	34.47	67.13
(i) Deferred tax assets (net)	1,641.65	1,377.76
(j) Other non-current assets	66.41	75.51
<b>Total Non current assets</b>	<b>10,335.31</b>	<b>9,205.98</b>
<b>(2) Current assets</b>		
(a) Inventories	654.60	747.03
(b) Financial assets		
Investments	742.74	3,061.05
Trade receivables	1,408.22	758.98
Cash and cash equivalents	649.31	64.64
Other bank balances	0.19	0.07
Loans	18.70	20.38
Other financial assets	99.50	112.61
(c) Other current assets	922.71	733.04
<b>Total Current assets</b>	<b>4,495.97</b>	<b>5,497.80</b>
<b>TOTAL- ASSETS</b>	<b>14,831.28</b>	<b>14,703.78</b>
<b>II. EQUITY AND LIABILITIES :</b>		
<b>(1) Equity</b>		
(a) Equity Share capital	135.78	137.52
(b) Other Equity	12,861.23	11,422.55
<b>Total Equity</b>	<b>12,997.01</b>	<b>11,560.07</b>
<b>(2) Non-current Liabilities</b>		
(a) Financial Liabilities		
Lease Liabilities	48.54	-
Other financial liabilities	18.93	18.32
(b) Long-term provisions	241.32	164.73
(c) Other non-current liabilities	31.07	54.21
<b>Total Non-current liabilities</b>	<b>339.86</b>	<b>237.26</b>
<b>(3) Current liabilities</b>		
(a) Financial Liabilities		
Trade payables		
i) Due to Micro and Small Enterprises	32.39	9.61
ii) Due to other than Micro and Small Enterprises	866.88	739.67
Lease Liabilities	56.94	-
Other financial liabilities	14.90	1,760.39
(b) Short-term provisions	297.58	192.22
(c) Other current liabilities	172.30	190.03
(d) Income tax liabilities (net)	53.42	14.53
<b>Total Current liabilities</b>	<b>1,494.41</b>	<b>2,906.45</b>
<b>Total Liabilities</b>	<b>1,834.27</b>	<b>3,143.71</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>14,831.28</b>	<b>14,703.78</b>

ML



2. Statement of Standalone Condensed Cash Flows for the Year ended March 31, 2020		
Particulars	(₹ In Million)	
	For Year Ended March 31, 2020 (Audited)	For Year Ended March 31, 2019 (Audited)
Net cash flow from operating activities		
Profit before tax	3,235.92	3,117.76
Operating profit before working capital changes	3,629.52	3,363.49
A) Net cash flow from operating activities	2,651.94	2,163.10
B) Net cash flow from investing activities	1,267.95	20.83
C) Net cash (used) in financing activities	(3,335.22)	(2,207.37)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	584.67	(23.44)
Add : Cash and cash equivalents at the beginning of the Year	64.64	88.08
Cash and cash equivalents at end of the Year	649.31	64.64

- The above statement of financial results ("the Statement") of the Company have been recommended by the Audit Committee and approved by the Board of Directors at their respective meeting.
- The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- The Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 million. The Company has acquired remaining 17.81% shareholding on April 06, 2019 for a consideration of ₹ 213.73 million in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
- Effective from April 01, 2019, the Company has adopted Ind AS 116 "Leases" and applied it to all lease contracts existing on April 01, 2019 using modified retrospective method. Accordingly, comparatives for previous period / year have not been retrospectively adjusted. The adoption of standard has resulted into creation of right of use lease asset by ₹ 179.80 million and lease liability by ₹ 190.89 million as at April 1, 2019. Also, the following effects have been given.

Changes (Increase/(decrease))	(₹ in million)	
	For Quarter ended March 31, 2020	For Year ended March 31, 2020
Depreciation and Amortisation	31.41	127.39
Finance costs on lease liability	2.50	13.06
Lease rent cost	(23.98)	(96.54)
Profit after tax	(6.47)	(28.57)

- During the quarter ended March 31, 2020, the Company concluded buy-back of 17,39,130 Equity Shares at a price of ₹ 575 per equity share from eligible shareholders of the Company on a proportionate basis through Tender Offer route in accordance with the provisions of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013 and rules made thereunder, as approved by the Board of Directors at their meeting held on July 03, 2019.
- The Board of Directors of the Company has declared and paid an interim dividend of ₹ 2.87/- (at the rate of 287 Percent) per equity share of the face value of ₹ 1/- each for the financial year 2019-20 at its meeting held on March 11, 2020.
- The figures for the quarter ended March 31, 2020 and the quarter ended March 31, 2019 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year.
- The Company continues to observe the Covid-19 impact on its business. This covers the monitoring of its impact on its supply-chain and customers. Conclusions on significant accounting judgements and estimates have been drawn after exercising requisite due care. Such judgements and estimates include, inter-alia, recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available as of the date of preparing the Company's financial results for the year ended March 31, 2020.
- Other Income includes Net Gain/(Loss) on fair value of financial assets, net gain on sales of investments, interest income, deferred capital subsidy, sundry creditors written back.
- On June 02, 2020, a new company, Eris Pharmaceuticals Private Limited has been incorporated as subsidiary of Eris Healthcare Private Limited (subsidiary of Eris Lifesciences Limited). Eris Healthcare Private Limited is having 76% shareholding in Eris Pharmaceuticals Private Limited. Eris Pharmaceuticals Private Limited will be engaged in manufacture of healthcare & OTC Products.
- Figures for the previous periods / year have been regrouped wherever considered necessary.

For Eris Lifesciences Limited,



Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925



Place: Ahmedabad  
Date: June 26, 2020

ML

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED  
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
ERIS LIFESCIENCES LIMITED**

**Opinion and Conclusion**

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2020 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2020 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2020 of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

**(a) Opinion on Annual Consolidated Financial Results**

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements / financial information of subsidiaries referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2020:

- (i) includes the results of the following entities;
  - i. Eris Lifesciences Limited (Parent)
  - ii. Aprica Healthcare Private Limited (Subsidiary)
  - iii. Kinedex Healthcare Private Limited (Subsidiary)
  - iv. Eris Therapeutics Private Limited (Subsidiary)
  - v. UTH Healthcare Limited (Subsidiary)
  - vi. Eris Healthcare Private Limited (Subsidiary)
- (ii) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31, 2020.

*ml*

**(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2020**

With respect to the Consolidated Financial Results for the quarter ended March 31, 2020, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the audit reports for the year ended on March 31, 2020 of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2020, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2020**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2020 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

**Management's Responsibilities for the Statement**

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2020, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2020 that give a true and fair view of the consolidated net profit and consolidated other comprehensive loss and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other



irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities**

#### **(a) Audit of the Consolidated Financial Results for the year ended March 31, 2020**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2020 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results / Financial Information of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2020**

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2020 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting



matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

As part of our annual audit we also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

### **Other Matters**

- As stated in Note 9 to the Statement, the figures for the corresponding quarter ended March 31, 2019 are the balancing figures between audited figures in respect of the full financial year then ended and the published year to date figures up to the third quarter of the previous financial year ended March 31, 2019. We have not issued a separate limited review report on the results and figures for the quarter ended March 31, 2019. Our report on the Statement is not modified in respect of this matter.
- The Statement includes the results for the Quarter ended March 31, 2020 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements / financial information of 5 subsidiaries included in the consolidated financial results, whose financial statements / financial information, before giving effect to the Consolidation adjustments, reflect total assets of Rs. 987.51 Millions as at March 31, 2020 and total revenues of Rs. 690.63 Millions, total net profit after tax of Rs. 79.90 Millions, total comprehensive income of Rs. 79.43 Millions and net cash inflows of Rs. 13.41 Millions for the year ended March 31, 2020 as considered in the Statement. These financial statements / financial information have been audited by the other auditors whose reports have been furnished to us by the Management, and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Manoj H. Dama  
Partner  
(Membership No. 107723)  
(UDIN: 20107723AAAAGY5824)

MUMBAI, June 26, 2020



STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2020

Particulars	[₹ in Million except per share data]				
	For Quarter Ended			For Year Ended	
	March 31, 2020 (refer note 9)	December 31, 2019 (Unaudited)	March 31, 2019 (refer note 9)	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>Revenue from Operations</b>					
Sale of products	2,440.85	2,617.53	2,110.85	10,581.83	9,672.02
Other operating income	44.81	46.46	37.36	158.76	149.59
<b>Total Revenue from Operations</b>	<b>2,485.66</b>	<b>2,663.99</b>	<b>2,148.21</b>	<b>10,740.59</b>	<b>9,821.61</b>
Other Income	(10.66)	84.66	117.29	153.96	316.94
<b>Total Income</b>	<b>2,475.00</b>	<b>2,748.65</b>	<b>2,265.50</b>	<b>10,894.55</b>	<b>10,138.55</b>
<b>Expenses</b>					
Cost of materials consumed	240.18	191.27	115.44	768.81	581.88
Purchase of stock-in-trade	168.37	153.00	339.26	732.43	1,089.32
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(37.56)	83.91	(105.95)	214.07	(134.22)
Employee benefits expense	556.04	524.29	472.31	2,056.93	1,906.59
Finance Costs	3.54	3.89	44.33	21.62	228.95
Depreciation and amortisation expense	143.18	126.98	112.07	502.58	363.54
Other expenses	786.29	943.71	705.64	3,284.61	2,928.91
<b>Total Expenses</b>	<b>1,860.04</b>	<b>2,027.05</b>	<b>1,683.10</b>	<b>7,581.05</b>	<b>6,964.97</b>
<b>Profit before Tax</b>	<b>614.96</b>	<b>721.60</b>	<b>582.40</b>	<b>3,313.50</b>	<b>3,173.58</b>
<b>Tax Expense</b>					
Current Tax	114.84	135.95	132.63	606.96	710.71
Deferred Tax	(62.60)	(49.04)	(89.07)	(258.53)	(448.60)
<b>Total Tax Expense</b>	<b>52.24</b>	<b>86.91</b>	<b>43.56</b>	<b>348.43</b>	<b>262.11</b>
<b>Net Profit for the period / year</b>	<b>562.72</b>	<b>634.69</b>	<b>538.84</b>	<b>2,965.07</b>	<b>2,911.47</b>
Attributable to :					
- Owners of the Company	562.72	634.69	540.87	2,964.97	2,907.96
- Non controlling interest	-	-	(2.03)	0.10	3.51
<b>Other Comprehensive Income</b>	<b>(6.84)</b>	<b>(0.74)</b>	<b>(2.94)</b>	<b>(12.18)</b>	<b>(1.13)</b>
Items that will not be reclassified to profit or loss	(10.45)	(1.13)	(4.27)	(18.63)	(1.71)
Income tax relating to items that will not be reclassified to profit or loss	3.61	0.39	1.33	6.45	0.58
<b>Total Comprehensive Income</b>	<b>555.88</b>	<b>633.95</b>	<b>535.90</b>	<b>2,952.89</b>	<b>2,910.34</b>
Attributable to :					
- Owners of the Company	555.88	633.95	537.93	2,952.79	2,906.83
- Non controlling interest	-	-	(2.03)	0.10	3.51
Paid Up Equity Share Capital (Face Value of ₹ 1 each)				135.78	137.52
Other Equity				12,827.56	11,367.66
Earnings Per Share (of ₹ 1 each) (not annualised) :					
Basic	4.13	4.62	3.93	21.61	21.15
Diluted	4.13	4.61	3.93	21.59	21.13

See accompanying notes to the consolidated financial results

ml



Registered & Corporate Office:

8<sup>th</sup> Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179402 - 03 Fax: +91 - 79 - 30179404 / 30451001 Email: eris@erislifesciences.com Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867

## Notes to the financial result

## 1. Statement of Consolidated Assets and Liabilities

(₹ in Million)

Particulars	As at	
	March 31, 2020 (Audited)	March 31, 2019 (Audited)
<b>I. ASSETS :</b>		
<b>(1) Non-current assets</b>		
(a) Property, Plant and Equipment	812.51	553.23
(b) Right-of-use asset	60.28	-
(c) Capital work-in-progress	-	7.48
(d) Goodwill	934.74	935.87
(e) Other Intangible assets	6,940.96	6,116.26
(f) Intangible assets under development	43.73	19.82
(g) Financial assets		
Investments	32.04	409.12
Other financial asset	83.12	76.87
(h) Income tax assets (net)	39.48	76.73
(i) Deferred tax assets (net)	1,709.11	1,447.94
(j) Other non-current assets	70.91	75.51
<b>Total Non-current assets</b>	<b>10,726.88</b>	<b>9,718.83</b>
<b>(2) Current assets</b>		
(a) Inventories	694.75	826.53
(b) Financial assets		
Investments	747.81	3,149.42
Trade receivables	1,568.84	839.76
Cash and cash equivalents	673.07	75.00
Other bank balances	0.19	0.07
Loans	9.35	21.25
Other financial assets	116.11	129.47
(c) Income tax assets (net)	-	1.26
(d) Other current assets	986.05	775.03
<b>Total Current assets</b>	<b>4,796.17</b>	<b>5,817.79</b>
<b>TOTAL- ASSETS</b>	<b>15,523.05</b>	<b>15,536.62</b>
<b>II. EQUITY AND LIABILITIES :</b>		
<b>(1) Equity</b>		
(a) Share capital	135.78	137.52
(b) Other Equity	12,827.56	11,367.66
Equity attributable to the owners of the Company	12,963.34	11,505.18
Non-controlling Interest	-	183.11
<b>Total Equity</b>	<b>12,963.34</b>	<b>11,688.29</b>
<b>(2) Non-current liabilities</b>		
(a) Financial Liabilities		
Long term Borrowings	-	2.93
Lease Liabilities	61.44	-
Other financial liabilities	54.38	23.51
(b) Long-term provisions	259.77	193.86
(c) Other non-current liabilities	31.07	55.71
(d) Deferred tax liabilities (net)	506.15	516.95
<b>Total Non-current liabilities</b>	<b>912.81</b>	<b>792.96</b>
<b>(3) Current liabilities</b>		
(a) Financial Liabilities		
Trade payables		
A) Due to Micro and Small Enterprises	33.08	9.61
B) Due to other than Micro and Small Enterprises	967.43	831.64
Lease Liabilities	59.99	-
Other financial liabilities	16.20	1,763.84
(b) Short-term provisions	301.97	210.29
(c) Other current liabilities	198.25	221.88
(d) Income tax liabilities (net)	69.98	18.11
<b>Total Current liabilities</b>	<b>1,646.90</b>	<b>3,055.37</b>
<b>Total Liabilities</b>	<b>2,559.71</b>	<b>3,848.33</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>15,523.05</b>	<b>15,536.62</b>

ML



2. Statement of Consolidated Condensed Cash Flows for the Year ended March 31, 2020

(₹ in million)

Particulars	For the Year Ended March 31, 2020 (Audited)	For the Year Ended March 31, 2019 (Audited)
Net cash flow from operating activities		
Profit before tax	3,313.50	3,173.58
Operating profit before working capital changes	3,755.87	3,478.59
A) Net cash flow from operating activities	2,711.10	2,229.96
B) Net cash flow from/ (used in) investing activities	1,232.88	(50.51)
C) Net cash (used) in financing activities	(3,345.91)	(2,210.53)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	598.07	(31.08)
Add : Cash and cash equivalents at the beginning of the Year	75.00	106.08
Cash and cash equivalents at end of the Year	673.07	75.00

3. The above statement of financial results ("the Statement") of the Group have been recommended by the Audit Committee and approved by the Board of Directors at their respective meeting.
4. The Group is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment"
5. The Parent Company on November 06, 2018 has acquired 6.71% shareholding of Kinedex Healthcare Private Limited for a consideration of ₹ 107.21 million. The Company has acquired remaining 17.81% shareholding on April 06, 2019 for a consideration of ₹ 213.73 million in Kinedex Healthcare Private Limited making it a wholly owned subsidiary.
6. Effective from April 01, 2019, the Group has adopted Ind AS 116 "Leases" and applied it to all lease contracts existing on April 01, 2019 using modified retrospective method. Accordingly, comparatives for previous period / year have not been retrospectively adjusted. The adoption of standard has resulted into creation of right of use lease asset by ₹ 196.78 million and lease liability by ₹ 209.37 million as at April 1, 2019. Also, the following effects have been given.

(₹ in million)

Changes [Increase/(decrease)]	For Quarter ended March 31, 2020	For Year ended March 31, 2020
Depreciation and Amortisation	33.39	135.33
Finance costs on lease liability	2.88	14.66
Lease rent cost	(25.03)	(100.67)
Profit after tax	(7.39)	(32.40)

7. During the quarter ended March 31, 2020, the Parent Company concluded buy-back of 17,39,130 Equity Shares at a price of ₹ 575 per equity share from eligible shareholders of the Parent Company on a proportionate basis through Tender Offer route in accordance with the provisions of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013 and rules made thereunder, as approved by the Board of Directors at their meeting held on July 03, 2019.
8. The Board of Directors of the Parent Company has declared and paid an interim dividend of Rs. 2.87/- (at the rate of 287 Percent) per equity share of the face value of Re. 1/- each for the financial year 2019-20 at its meeting held on March 11, 2020.
9. The figures for the quarter ended March 31, 2020 and the quarter ended March 31, 2019 as reported in these financial results are the balancing figures between the Audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year.
10. The Group continues to observe the Covid-19 impact on its business. This covers the monitoring of its impact on its supply-chain and customers. Conclusions on significant accounting judgements and estimates have been drawn after exercising requisite due care. Such judgements and estimates include, inter-alia, recoverability of receivables, assessment of impairment of goodwill and intangibles, investments and inventory, based on the information available as of the date of preparing the Group's financial results for the year ended March 31, 2020.
11. Other Income includes Net Gain/(Loss) on fair value of financial assets, net gain on sales of investments, interest income, deferred capital subsidy, sundry creditors written back.
12. On June 02, 2020, a new company, Eris Pharmaceuticals Private Limited has been incorporated as subsidiary of Eris Healthcare Private Limited (subsidiary of Eris Lifesciences Limited). Eris Healthcare Private Limited is having 76% shareholding in Eris Pharmaceuticals Private Limited. Eris Pharmaceuticals Private Limited will be engaged in manufacture of healthcare & OTC Products.
13. Figures for the previous periods / year have been regrouped wherever considered necessary.

*ml*

For Eris Lifesciences Limited,

*Amit Bakshi*

Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925



Place: Ahmedabad  
Date: June 26, 2020